A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Erica Brivio(Princess Máxima Center), C. Michel Zwaan(Princess Máxima Center), Claudia Rössig(Klinik und Poliklinik für Kinder- und Jugendmedizin), Ingrid Øra(Karolinska University Hospital), Inge M. van der Sluis(Princess Máxima Center), Franco Locatelli(Bambino Gesù Children's Hospital), Vincent H. J. van der Velden(Erasmus MC), Christiane Chen‐Santel(Universitätsmedizin Rostock), Adriana Thano(The Netherlands Cancer Institute), Monique L. den Boer(Princess Máxima Center), Luciana Vinti(Bambino Gesù Children's Hospital), Anneke C. J. Ammerlaan(Princess Máxima Center), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Lucie Šrámková(University Hospital in Motol), Bella Bielorai, Karsten Nysom(Copenhagen University Hospital), Ying Chen(Pfizer (United States)), Barbara Sleight(Pfizer (United States)), Marta López‐Yurda(The Netherlands Cancer Institute), Andrea Malone(Children's Health Ireland at Crumlin), Benoît Brethon(Hôpital Saint-Louis)
Blood
October 16, 2020
Cited by 93


Related Papers